Rafael Holdings Inc (RFL) - News Archive

: This article presents an analysis of the recent preliminary data concerning the Phase 3 open-label sub-study evaluating Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin) for the treatment of Niemann-Pick disease type C...

In an era where the advancement of medical treatments for rare diseases is of paramount importance, Rafael Holdings has reaffirmed its commitment to the development of Trappsol Cyclo, a promising investigational drug fo...

Breaking News Cyclo Therapeutics’ Phase 3 Clinical Trial for Niemann-Pick Disease Type C1 Fully Enrolled, Interim Analysis Results Anticipated in 2025City, State – In a groundbreaking development for patients suffering...

In a notable update for investors and stakeholders, Rafael Holdings, Inc. (NYSE: RFL) has reported its financial results for the second quarter of fiscal 2025, during which the company showcased its diverse portfolio an...

In a significant development that promises to reshape the landscape of rare disease treatment, Rafael Holdings (NYSE: RFL) has entered into a definitive merger agreement with Cyclo Therapeutics. This strategic partnersh...